DK0956034T3 - Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin - Google Patents

Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin

Info

Publication number: DK0956034T3
Authority: DK; Denmark
Prior art keywords: rapamycin; hydroxyethyl; cyclosporin; treatment; pharmaceutical compositions
Prior art date: 1996-07-30

Application number

DK97937526T

Other languages

Danish (da)

English (en)

Inventor

Gerhard Zenke

Hendrik J Schuurman

Barbara Haeberlin

Armin Meinzer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-30

Filing date

1997-07-29

Publication date

2002-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0956034(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-30 Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en

1997-03-18 Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en

1997-07-29 Application filed by Novartis Ag filed Critical Novartis Ag

2002-12-16 Application granted granted Critical

2002-12-16 Publication of DK0956034T3 publication Critical patent/DK0956034T3/da

Links

HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title abstract 3
229930105110 Cyclosporin A Natural products 0.000 title abstract 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 2
108010036949 Cyclosporine Proteins 0.000 title abstract 2
206010052779 Transplant rejections Diseases 0.000 title abstract 2
230000001363 autoimmune Effects 0.000 title abstract 2
229960001265 ciclosporin Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000004968 inflammatory condition Effects 0.000 title 1
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000035897 transcription Effects 0.000 abstract 2
238000013518 transcription Methods 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
-1 e.g. Chemical compound 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Graft Or Block Polymers (AREA)
Medicinal Preparation (AREA)

DK97937526T 1996-07-30 1997-07-29 Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin DK0956034T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9615942.1A GB9615942D0 (en)	1996-07-30	1996-07-30	Organic compounds
GBGB9705684.0A GB9705684D0 (en)	1997-03-18	1997-03-18	Organic compounds
PCT/EP1997/004123 WO1998004279A1 (fr)	1996-07-30	1997-07-29	Compositions pharmaceutiques utiles dans le traitement de rejets de greffe, d'etats auto-immuns ou inflammatoires, comprenant de la cyclosporine a et de la 40-0-(2-hydroxyethyl)-rapamycine

Publications (1)

Publication Number	Publication Date
DK0956034T3 true DK0956034T3 (da)	2002-12-16

Family

ID=26309775

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK97937526T DK0956034T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
DK01131018T DK1208847T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK01131018T DK1208847T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande

Country Status (14)

Country	Link
US (2)	US6239124B1 (fr)
EP (2)	EP0956034B1 (fr)
JP (2)	JP3942641B2 (fr)
AT (2)	ATE340586T1 (fr)
AU (1)	AU730781B2 (fr)
CA (1)	CA2261666C (fr)
CY (1)	CY2391B1 (fr)
DE (2)	DE69714861T2 (fr)
DK (2)	DK0956034T3 (fr)
ES (2)	ES2182112T3 (fr)
NZ (1)	NZ333657A (fr)
PT (2)	PT956034E (fr)
SI (1)	SI1208847T1 (fr)
WO (1)	WO1998004279A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI0649651T1 (en) *	1993-09-28	2001-02-28	Scherer Gmbh R P	Soft gelatin capsule manufacture
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
PT956034E (pt) *	1996-07-30	2002-12-31	Novartis Ag	Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
GB9825632D0 (en) *	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
GB9826882D0 (en)	1998-12-07	1999-01-27	Novartis Ag	Organic compounds
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2000067773A2 (fr) *	1999-05-10	2000-11-16	Novartis Ag	Composes organiques
CA2427569C (fr) *	2000-11-03	2010-07-27	Matrix Therapeutics Limited	Agonistes selectifs du recepteur de glucocorticoides
US20020127263A1 (en) *	2001-02-27	2002-09-12	Wenda Carlyle	Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
EP1435910B9 (fr) *	2001-10-19	2010-02-03	Isotechnika Inc.	Nouveaux preconcentres en microemulsion d'analogues de cyclosporine
CN100415227C (zh) *	2001-10-25	2008-09-03	阿特罗吉尼克斯公司	化合物在制备用于治疗移植排斥的药物中的应用
US7682387B2 (en)	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) *	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en) *	2002-06-28	2006-09-19	Hobai Ion A	Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
MXPA05000139A (es)	2002-07-16	2005-04-11	Biotica Tech Ltd	Produccion de policetidos y otros productos naturales.
US20060171984A1 (en) *	2002-09-06	2006-08-03	Cromack Keith R	Device having hydration inhibitor
CA2498191C (fr) *	2002-09-18	2012-04-10	Trustees Of The University Of Pennsylvania	Methode d'inhibition de la neovascularisation choroidienne
US8202530B2 (en) *	2002-09-27	2012-06-19	Advanced Cardiovascular Systems, Inc.	Biocompatible coatings for stents
AR043504A1 (es) *	2003-03-17	2005-08-03	Novartis Ag	Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
WO2005020994A1 (fr) *	2003-08-29	2005-03-10	Lifecycle Pharma A/S	Dispersions solides comprenant du tacrolimus
AU2004274026A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US20110104186A1 (en)	2004-06-24	2011-05-05	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
JP2008530127A (ja)	2005-02-09	2008-08-07	マクサイト，インコーポレイテッド	眼の処置のための処方物
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
RU2007127499A (ru) *	2005-02-15	2009-03-27	Вайет (Us)	Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
KR20190062506A (ko)	2005-02-18	2019-06-05	아브락시스 바이오사이언스, 엘엘씨	치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) *	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
EP1896018A2 (fr)	2005-03-11	2008-03-12	Biotica Technology Limited	Utilisations medicales de 39-demethoxy-rapamicyne et ses analogues
AU2006227116A1 (en) *	2005-03-21	2006-09-28	Santen Pharmaceutical Co., Ltd.	Drug delivery systems for treatment of diseases or conditions
EA200702216A1 (ru)	2005-04-12	2008-08-29	Элан Фарма Интернэшнл Лимитед	Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
WO2006119130A2 (fr) *	2005-04-29	2006-11-09	Atrium Medical Corporation	Enrobage de diffusion de médicament utilisable avec un dispositif médical, et méthodes de traitement d'une lésion vasculaire
NZ565846A (en) *	2005-07-18	2011-12-22	Horizon Therapeutics Inc	Medicaments containing famotidine and ibuprofen and administration of same
US8067451B2 (en)	2006-07-18	2011-11-29	Horizon Pharma Usa, Inc.	Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Unit dose form for administration of ibuprofen
US20080021078A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Methods and medicaments for administration of ibuprofen
WO2007092620A2 (fr)	2006-02-09	2007-08-16	Macusight, Inc.	Formulations stables et leurs procedes de preparation et d'utilisation
AU2007230964B2 (en)	2006-03-23	2012-07-19	Santen Pharmaceutical Co., Ltd.	Formulations and methods for vascular permeability-related diseases or conditions
US8067033B2 (en) *	2007-11-30	2011-11-29	Horizon Pharma Usa, Inc.	Stable compositions of famotidine and ibuprofen
EP2063873A2 (fr) *	2006-08-31	2009-06-03	Horizon Therapeutics, Inc.	Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
WO2011123395A1 (fr)	2010-03-29	2011-10-06	Abraxis Bioscience, Llc	Méthodes de traitement du cancer
EP2552439B1 (fr)	2010-03-29	2022-07-20	Abraxis BioScience, LLC	Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
PH12012502380B1 (en)	2010-06-04	2019-08-23	Abraxis Bioscience Llc	Methods of treatment of pancreatic cancer
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2671583A4 (fr) *	2011-01-31	2014-09-03	Univ Osaka	Médicament à usage externe pour traiter un trouble cutané et procédé pour produire celui-ci
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US9220759B2 (en)	2012-02-23	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en)	2012-03-30	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (fr)	2012-09-07	2014-03-12	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.	Composés pour le traitement de troubles neurodégénératifs
ES2797376T3 (es)	2013-01-24	2020-12-02	Palvella Therapeutics Inc	Composiciones para la administración transdérmica de inhibidores de mTOR
EP3049020B1 (fr)	2013-09-24	2022-06-15	Giner Life Sciences, Inc.	Système pour le traitement gazeux d'un implant cellulaire
WO2016033556A1 (fr)	2014-08-28	2016-03-03	Lipocine Inc.	Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016033549A2 (fr)	2014-08-28	2016-03-03	Lipocine Inc.	Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
WO2017079736A1 (fr) *	2015-11-06	2017-05-11	The Trustees Of Columbia University In The City Of New York	Profilage de protéines exosomales pour la détection du rejet de greffe cardiaque
RU2019114817A (ru)	2016-11-15	2020-11-16	Джинер Лайф Сайенс, Инк.	Устройство чрезкожной диффузии газов, подходящее для применения с подкожным имплантатом
WO2018098501A1 (fr)	2016-11-28	2018-05-31	Lipocine Inc.	Traitement oral à base d'undécanoate de testostérone
AU2018205253B2 (en)	2017-01-06	2022-01-13	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
AU2018219317A1 (en)	2017-02-10	2019-09-26	Mount Tam Therapeutics, Inc.	Rapamycin analog
EP3618916A4 (fr)	2017-05-04	2021-04-14	Giner Life Sciences, Inc.	Dispositif implantable de distribution robuste, de gaz et procédés, systèmes et dispositifs l'utilisant
JP2021530463A (ja)	2018-07-02	2021-11-11	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物および使用方法
EP3824296A4 (fr)	2018-07-20	2022-04-27	Lipocine Inc.	Maladie du foie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
DK0562853T3 (da)	1992-03-27	1996-07-01	American Home Prod	29-Demethoxyrapamycin til fremkaldelse af immunsuppression
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB2278780B (en)	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
GB9601120D0 (en) *	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
PT956034E (pt) *	1996-07-30	2002-12-31	Novartis Ag	Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
WO2000067773A2 (fr) *	1999-05-10	2000-11-16	Novartis Ag	Composes organiques

1997
- 1997-07-29 PT PT97937526T patent/PT956034E/pt unknown
- 1997-07-29 PT PT01131018T patent/PT1208847E/pt unknown
- 1997-07-29 ES ES97937526T patent/ES2182112T3/es not_active Expired - Lifetime
- 1997-07-29 EP EP97937526A patent/EP0956034B1/fr not_active Expired - Lifetime
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 JP JP50851398A patent/JP3942641B2/ja not_active Expired - Lifetime
- 1997-07-29 AT AT01131018T patent/ATE340586T1/de active
- 1997-07-29 DE DE69714861T patent/DE69714861T2/de not_active Expired - Lifetime
- 1997-07-29 DK DK97937526T patent/DK0956034T3/da active
- 1997-07-29 CA CA2261666A patent/CA2261666C/fr not_active Expired - Lifetime
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/fr not_active Ceased
- 1997-07-29 ES ES01131018T patent/ES2270948T3/es not_active Expired - Lifetime
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
- 1997-07-29 EP EP01131018A patent/EP1208847B8/fr not_active Expired - Lifetime
- 1997-07-29 NZ NZ333657A patent/NZ333657A/xx not_active IP Right Cessation
- 1997-07-29 DK DK01131018T patent/DK1208847T3/da active
- 1997-07-29 AT AT97937526T patent/ATE222502T1/de active
- 1997-07-29 DE DE69736750T patent/DE69736750T2/de not_active Expired - Lifetime
- 1997-07-29 SI SI9730756T patent/SI1208847T1/sl unknown
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/xx unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2182112T3 (es)	2003-03-01
AU730781B2 (en)	2001-03-15
DE69736750D1 (de)	2006-11-09
EP1208847B1 (fr)	2006-09-27
ATE222502T1 (de)	2002-09-15
ES2270948T3 (es)	2007-04-16
HK1023720A1 (en)	2000-09-22
ATE340586T1 (de)	2006-10-15
EP1208847A3 (fr)	2002-06-12
PT956034E (pt)	2002-12-31
JP4149905B2 (ja)	2008-09-17
CA2261666C (fr)	2010-09-14
US20010008888A1 (en)	2001-07-19
EP1208847A2 (fr)	2002-05-29
US6455518B2 (en)	2002-09-24
DE69714861D1 (de)	2002-09-26
SI1208847T1 (sl)	2007-06-30
JP2000505806A (ja)	2000-05-16
CY2391B1 (en)	2004-09-10
WO1998004279A1 (fr)	1998-02-05
CA2261666A1 (fr)	1998-02-05
JP3942641B2 (ja)	2007-07-11
DE69714861T2 (de)	2003-05-22
AU4012497A (en)	1998-02-20
EP0956034B1 (fr)	2002-08-21
JP2004210767A (ja)	2004-07-29
PT1208847E (pt)	2007-07-24
DK1208847T3 (da)	2007-01-08
US6239124B1 (en)	2001-05-29
NZ333657A (en)	2000-05-26
DE69736750T2 (de)	2007-08-16
EP0956034A1 (fr)	1999-11-17
EP1208847B8 (fr)	2007-02-14

Publication	Publication Date	Title
DK0956034T3 (da)	2002-12-16	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
DK0401747T3 (da)	2004-03-08	Anvendelse af rapamycin og derivater og prolægemidler deraf til fremstilling af et lægemiddel til hæmning af transplantatafstødning hos pattedyr
MX9101869A (es)	1993-04-01	Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
DE69736316D1 (de)	2006-08-24	CDMA Signalübertragung über eine analoge optische Leitung
ATE183178T1 (de)	1999-08-15	Neue immunsuppressive verbindungen
TR199701567T1 (xx)	1998-04-21	Rapamisin t�revleri.
DK1339438T3 (da)	2006-02-13	Forebyggelse af transplantatafvisning i ojet
TR199801919T2 (xx)	1999-02-22	Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
BR0314397A (pt)	2005-08-09	Formulações orais
DK0896544T3 (da)	2003-05-05	Kombination af en somatostatinanalog og en rapamycin
WO2002100148A3 (fr)	2004-04-22	Traitement ou prophylaxie du rejet des greffes de cellules produisant de l'insuline
WO2004049907A3 (fr)	2005-04-28	Compositions et méthodes de traitement de greffons
DK0408711T3 (da)	1994-06-06	S-adenosylmethionin til behandling af pancreatitis og immunafstødning ved pancreastransplantationer
DK1891961T3 (da)	2009-12-21	Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning
DK1562571T3 (da)	2011-12-05	Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
CA2543665A1 (fr)	2005-05-26	Cci-779 pour traiter des lymphomes a cellules du manteau
SI0956034T1 (en)	2002-12-31	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin
ECSP961769A (es)	1997-10-03	Derivados de rapamicina